BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 17362500)

  • 1. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population.
    Elkiran ET; Mar N; Aygen B; Gursu F; Karaoglu A; Koca S
    BMC Cancer; 2007 Mar; 7():48. PubMed ID: 17362500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidative status and serum PON1 activity in beta-thalassemia minor.
    Selek S; Aslan M; Horoz M; Gur M; Erel O
    Clin Biochem; 2007 Mar; 40(5-6):287-91. PubMed ID: 17296173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum lipid profile paraoxonase and arylesterase activities in psoriasis.
    Toker A; Kadi M; Yildirim AK; Aksoy H; Akçay F
    Cell Biochem Funct; 2009 Apr; 27(3):176-80. PubMed ID: 19330810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
    Dirican M; Akca R; Sarandol E; Dilek K
    J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation.
    Serhatlioglu S; Gursu MF; Gulcu F; Canatan H; Godekmerdan A
    Cell Biochem Funct; 2003 Dec; 21(4):371-5. PubMed ID: 14624476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer.
    Camuzcuoglu H; Arioz DT; Toy H; Kurt S; Celik H; Erel O
    Gynecol Oncol; 2009 Mar; 112(3):481-5. PubMed ID: 19101714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients.
    Yildiz A; Gur M; Demirbag R; Yilmaz R; Akyol S; Aslan M; Erel O
    Clin Biochem; 2008 Jul; 41(10-11):779-84. PubMed ID: 18355454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.
    Juretić D; Motejlkova A; Kunović B; Rekić B; Flegar-Mestrić Z; Vujić L; Mesić R; Lukac-Bajalo J; Simeon-Rudolf V
    Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraoxonase and arylesterase activities in coronary artery disease.
    Gur M; Aslan M; Yildiz A; Demirbag R; Yilmaz R; Selek S; Erel O; Ozdogru I
    Eur J Clin Invest; 2006 Nov; 36(11):779-87. PubMed ID: 17032345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early effects of sodium valproate monotherapy on serum paraoxonase/arylesterase activities.
    Karikas GA; Schulpis KH; Bartzeliotou A; Regoutas S; Thanopoulou C; Papaevangelou V; Giannoulia-Karantana A; Papassotiriou I; Fytou-Pallikari A
    Scand J Clin Lab Invest; 2009; 69(1):31-5. PubMed ID: 19016076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of oxygen derived free radicals producer (xanthine oxidase) and scavenger (paraoxonase1) enzymes and lipid parameters in different cancer patients.
    Samra ZQ; Pervaiz S; Shaheen S; Dar N; Athar MA
    Clin Lab; 2011; 57(9-10):741-7. PubMed ID: 22029190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
    Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals.
    Bajnok L; Seres I; Varga Z; Jeges S; Peti A; Karanyi Z; Juhasz A; Csongradi E; Mezosi E; Nagy EV; Paragh G
    Metabolism; 2007 Nov; 56(11):1542-9. PubMed ID: 17950106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
    Rosenblat M; Karry R; Aviram M
    Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis.
    Kannampuzha J; Darling PB; Maguire GF; Donnelly S; McFarlane P; Chan CT; Connelly PW
    Clin Nephrol; 2010 Feb; 73(2):131-8. PubMed ID: 20129020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease].
    Gamboa R; Regalado JC; Huesca-Gómez C; Posadas-Romero C; Verdejo Paris J; Vargas-Alarcón G; Pérez-Méndez O
    Arch Cardiol Mex; 2008; 78(4):360-8. PubMed ID: 19205543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of serum paraoxonase (an HDL-cholesterol-associated lipophilic antioxidant) and arylesterase activities in severe preeclamptic women.
    Kumru S; Aydin S; Gursu MF; Ozcan Z
    Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):177-81. PubMed ID: 15140512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.
    Yavuz DG; Yüksel M; Deyneli O; Ozen Y; Aydin H; Akalin S
    Clin Endocrinol (Oxf); 2004 Oct; 61(4):515-21. PubMed ID: 15473886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum paraoxonase levels in gastric cancer.
    Akçay MN; Yilmaz I; Polat MF; Akçay G
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():cclxxiii-cclxxv. PubMed ID: 15244199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum paraoxonase levels in pancreatic cancer.
    Akçay MN; Polat MF; Yilmaz I; Akçay G
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccxxv-ccxxvii. PubMed ID: 15244186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.